Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel W Visscher

Showing results (71-80 of 122) with videos related to

Pageof 13
Sort By:
Breast Cancer Research and Treatment|July 24, 2015
Gene signature model for breast cancer risk prediction for women with sclerosing adenosisAmy C Degnim, Aziza Nassar, Melody Stallings-Mann, et al.
Breast Cancer Research and Treatment|February 6, 2016
Natural history of age-related lobular involution and impact on breast cancer riskDerek C Radisky, Daniel W Visscher, Ryan D Frank, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 29, 2020
Breast Cancer Risk and Use of Nonsteroidal Anti-inflammatory Agents After a Benign Breast BiopsyMark E Sherman, Robert A Vierkant, Suneetha Kaggal, et al.
Plos One|November 16, 2013
Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistanceSanjib Bhattacharyya, Sounik Saha, Karuna Giri, et al.
Breast Cancer Research and Treatment|November 15, 2022
Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriersJoshua Ogony, Tanya L Hoskin, Melody Stallings-Mann, et al.
Breast Cancer Research and Treatment|February 26, 2008
Breast cancer risk in women with radial scars in benign breast biopsiesJena C Berg, Daniel W Visscher, Robert A Vierkant, et al.
Clinical Breast Cancer|December 31, 2005
Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252Edith A Perez, Vera J Suman, Kendrith M Rowland, et al.
Breast Cancer Research : BCR|December 21, 2017
Association between mammographic breast density and histologic features of benign breast diseaseKarthik Ghosh, Robert A Vierkant, Ryan D Frank, et al.
Breast Cancer Research and Treatment|July 29, 2017
Postlactational involution biomarkers plasminogen and phospho-STAT3 are linked with active age-related lobular involutionMelody L Stallings-Mann, Ethan P Heinzen, Robert A Vierkant, et al.
Gynecologic Oncology|January 27, 2015
Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo ClinicAndrea E Wahner Hendrickson, Kieran M Hawthorne, Ellen L Goode, et al.
Pageof 13

Showing results (71-80 of 122) with videos related to

Sort By:
Pageof 13
Breast Cancer Research and Treatment|July 24, 2015
Gene signature model for breast cancer risk prediction for women with sclerosing adenosisAmy C Degnim, Aziza Nassar, Melody Stallings-Mann, et al.
Breast Cancer Research and Treatment|February 6, 2016
Natural history of age-related lobular involution and impact on breast cancer riskDerek C Radisky, Daniel W Visscher, Ryan D Frank, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 29, 2020
Breast Cancer Risk and Use of Nonsteroidal Anti-inflammatory Agents After a Benign Breast BiopsyMark E Sherman, Robert A Vierkant, Suneetha Kaggal, et al.
Plos One|November 16, 2013
Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistanceSanjib Bhattacharyya, Sounik Saha, Karuna Giri, et al.
Breast Cancer Research and Treatment|November 15, 2022
Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriersJoshua Ogony, Tanya L Hoskin, Melody Stallings-Mann, et al.
Breast Cancer Research and Treatment|February 26, 2008
Breast cancer risk in women with radial scars in benign breast biopsiesJena C Berg, Daniel W Visscher, Robert A Vierkant, et al.
Clinical Breast Cancer|December 31, 2005
Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252Edith A Perez, Vera J Suman, Kendrith M Rowland, et al.
Breast Cancer Research : BCR|December 21, 2017
Association between mammographic breast density and histologic features of benign breast diseaseKarthik Ghosh, Robert A Vierkant, Ryan D Frank, et al.
Breast Cancer Research and Treatment|July 29, 2017
Postlactational involution biomarkers plasminogen and phospho-STAT3 are linked with active age-related lobular involutionMelody L Stallings-Mann, Ethan P Heinzen, Robert A Vierkant, et al.
Gynecologic Oncology|January 27, 2015
Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo ClinicAndrea E Wahner Hendrickson, Kieran M Hawthorne, Ellen L Goode, et al.
Pageof 13